Bisphosphonate-related osteonecrosis of the jaws. A severe side effect of bisphosphonate therapy

Title:

Bisphosphonate-related osteonecrosis of the jaws. A severe side effect of bisphosphonate therapy
Bisphosphonate-related osteonecrosis of the jaws. A severe side effect of bisphosphonate therapy

Creator:

Janovská, Zuzana

Contributor:

Janovská, Zuzana

Identifier:

https://cdk.lib.cas.cz/client/handle/uuid:bmc12040498-1949c5ec-38d8-4984-89bf-3a8a75cd6cd7
uuid:bmc12040498-1949c5ec-38d8-4984-89bf-3a8a75cd6cd7
local:bmc12040498
http://www.lfhk.cuni.cz/article.asp?nArticleID=4434&nDepartmentID=1288&nLanguageID=2
local: bmc12040498

Subject:

lidé, nemoci čelistí--terapie, bisfosfonátová osteonekróza čelistí--etiologie--klasifikace--patologie, bisfosfonáty--klasifikace--škodlivé účinky--terapeutické užití, nemoci kostí, and rizikové faktory

Type:

model:article, article, Text, práce podpořená grantem, and TEXT

Format:

braille, text, and regular print

Description:

Bisphosphonates (BP) are potent inhibitors of bone resorption used mainly in the treatment of metastatic bone disease and osteoporosis. By inhibiting bone resorption, they prevent complications as pathological fracture, pain, tumor-induced hypercalcemia. Even though patient’s benefit of BP therapy is huge, various side effects may develop. Bisphosphonate-related osteonecrosis of the jaws (BRONJ) is among the most serious ones. Oncologic patients receiving high doses of BP intravenously are at high risk of BRONJ development. BPs impair bone turnover leading to compromised bone healing which may result in the exposure of necrotic bone in the oral cavity frequently following tooth extraction or trauma of the oral mucosa. Frank bone exposure may be complicated by secondary infection leading to osteomyelitis development with various symptoms and radiological findings. In the management of BRONJ, conservative therapy aiming to reduce the symptoms plays the main role. In patients with extensive bone involvement resective surgery may lead to complete recovery, provided that the procedure is correctly indicated. Since the treatment of BRONJ is difficult, prevention is the main goal. Therefore in high risk patients dental preventive measures should be taken prior to bisphosphonate administration. This requires adequate communication between the prescribing physician, the patient and the dentist., Zuzana Janovská, and Literatura 46

Language:

English

Rights:

http://creativecommons.org/publicdomain/mark/1.0/
policy:public

Relation:

Acta medica (Hradec Králové)--MED00010947

Source:

Acta medica (Hradec Králové) | 2012 Volume:55 | Number:3

Harvested from:

CDK

Metadata only:

false

Date:

2012